Ontipria (Tiotropium Bromide)

Tiotropium bromide, the active ingredient in Ontipria, is a long‑acting muscarinic antagonist presented as a inhalation powder for oral inhalation use. It is indicated for maintenance therapy in patients with chronic obstructive pulmonary disease, helping to improve lung function and reduce exacerbations. GNH USA supplies Ontipria as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Ontipria as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Ontipria is a bronchodilator that acts on the airways of patients with chronic obstructive pulmonary disease.

- Chronic obstructive pulmonary disease (COPD): Improves airflow and reduces the frequency of exacerbations. - Asthma (as add‑on therapy): Provides additional bronchodilation when standard inhaled therapies are insufficient. - Chronic bronchitis: Helps to ease breathing difficulty associated with persistent airway inflammation.

Adverse reactions to Ontipria are generally mild to moderate and vary with individual sensitivity.

Common Side Effects: - Dry mouth - Cough - Throat irritation - Upper respiratory tract infection - Headache - Nasal congestion

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (anaphylaxis) - Angio‑ema - Persistent urinary retention - Tachycardia - Worsening of glaucoma

When using Ontipria, certain precautions should be observed to ensure safety and effectiveness.

- Assess respiratory status: Perform baseline lung function testing before initiating therapy. - Monitor for urinary retention: Patients with prostate enlargement should be observed for difficulty voiding. - Evaluate glaucoma risk: Use cautiously in patients with narrow‑angle glaucoma. - Review concomitant medications: Check for other anticholinergic agents that may increase anticholinergic load. - Store at ambient temperature: Keep below 25°C, protect from moisture and keep in original packaging.

Ontipria may interact with other medicines that influence anticholinergic activity or respiratory function.

Major Interactions (Avoid):\n- Other long‑acting anticholinergics: Combined use can increase risk of severe anticholinergic effects. - Beta‑agonist inhalers in high doses: May potentiate cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Antihistamines and tricyclic antidepressants: May add to dry‑mouth and urinary‑retention effects. - Theophylline: Requires monitoring of respiratory status and possible dose adjustment. - Ketamine: Potential for additive bronchodilatory effects. - Inhaled corticosteroids: May increase local irritation but are generally safe together.